Celsion Corporation

Short Term Long Term Short Term Comparison Long Term Comparison
  • CLSN
  • 1d1.40%
  • 1w-0.54%
  • 1m-7.05%
  • 1y-86.58%
ATH
  • ATH Price$132,448.00
  • ATH Date2000-03-02
  • % since ATH-100.00%
  • % to ATH9,134,244.83%
ATL
  • ATL Price$1.43
  • ATL Date2022-11-21
  • % from ATL1.40%
  • Last Low Price$1.43
  • Last Low Date2022-11-21
  • % From Last Low1.40%
IPO
  • IPO Price$0.52
  • % Current ROI USD278.85%
  • ATH Price$132,448.00
  • % ROI ATH 926,209,790.21%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CLSN"]

Key Data [addtoany]

Current price $1.45
Sector Healthcare
Industry Biotechnology
Today's High/Low $1.46/$1.4
Volume 29,458.00
Previous Close $1.43
52 Week High/Low $11.805/$1.3859
Market Cap 13,913,531.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-3.78
Annualized Dividend $0
$1.45
[addtoany]

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines.
Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer.
The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers.
Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity